2-Arylquinolines as novel anticancer agents with dual EGFR/FAK kinase inhibitory activity: synthesis, biological evaluation, and molecular modelling insights is a research paper published in Journal of Enzyme Inhibition and Medicinal Chemistry (2021). On theSindex it has a DataRank of 0. It has been cited 41 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: R01 CA100768
NCI NIH HHS
Grant: R01 CA160911
NCI NIH HHS
Grant: R01 CA238042
NCI NIH HHS
Grant: T32 CA121938
Intramural NIH HHS
Grant: Z01 BC006161
National Institutes of Health
Grant: 5R01CA238042-05
Integrators of Metastatic Potential
National Institutes of Health
Grant: 1R01CA160911-01A1
Modulation of G proteins by Growth Factors
National Institutes of Health
Grant: 5T32CA121938-14
UCSD Cancer Center Training Program in Drug Development
National Institutes of Health
Grant: 1Z01BC006161-19
DNA Topoisomerases as Target of Action of Anticancer Dru
National Institutes of Health
Grant: 3R01CA100768-10S1
Spatial Regulation of RGS and G Protein Signaling
FWCI
1.99
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
2-Arylquinolines as novel anticancer agents with dual EGFR/FAK kinase inhibitory activity: synthesis, biological evaluation, and molecular modelling insights
2-Arylquinolines as novel anticancer agents with dual EGFR/FAK kinase inhibitory activity: synthesis, biological evaluation, and molecular modelling insights